A comprehensive review of immune checkpoint inhibitors for cancer treatment
The DOI matches its Crossref record; 612 of the 626 references it cites were found in a registry or an index.
Abstract
Immunology-based therapies are emerging as an effective cancer treatment, using the body's immune system to target tumors. Immune checkpoints, which regulate immune responses to prevent tissue damage and autoimmunity, are often exploited by cancer cells to avoid destruction. The discovery of checkpoint proteins like PD-1/PD-L1 and CTLA-4 was pivotal in developing cancer immunotherapy. Immune checkpoint inhibitors (ICIs) have shown great success, with FDA-approved drugs like PD-1 inhibitors (Nivolumab, Pembrolizumab, Cemiplimab), PD-L1 inhibitors (Atezolizumab, Durvalumab, Avelumab), and CTLA-4 inhibitors (Ipilimumab, Tremelimumab), alongside LAG-3 inhibitor Relatlimab. Research continues on new checkpoints like TIM-3, VISTA, B7-H3, BTLA, and TIGIT. Biomarkers like PDL-1 expression, tumor mutation burden, interferon-γ presence, microbiome composition, and extracellular matrix characteristics play a crucial role in predicting responses to immunotherapy with checkpoint inhibitors. Despite their effectiveness, not all patients experience the same level of benefit, and organ-specific immune-related adverse events (irAEs) such as rash or itching, colitis, diarrhea, hyperthyroidism, and hypothyroidism may occur. Given the rapid advancements in this field and the variability in patient outcomes, there is an urgent need for a comprehensive review that consolidates the latest findings on immune checkpoint inhibitors, covering their clinical status, biomarkers, resistance mechanisms, strategies to overcome resistance, and associated adverse effects. This review aims to fill this gap by providing an analysis of the current clinical status of ICIs, emerging biomarkers, mechanisms of resistance, strategies to enhance therapeutic efficacy, and assessment of adverse effects. This review is crucial to furthering our understanding of ICIs and optimizing their application in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Cited by
Items 101–200 of 252
Nervo, A., Gruosso, G., Marino, M., Migliore, E., Rubiolo, M., Vaccaro, E., & Arvat, E. (2025) · Clinical Endocrinology · doi:10.1111/cen.70023 · Cited by 1
Song, Z., Zhang, M., Wu, M., Zhang, C., Huang, W., & Zeng, S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118683 · Cited by 1
Role of microbiota in the outcome of immune checkpoint inhibition therapy of cancer
Rijkers, G. T., Langcauon, Y., van Leersum, P., Popović, L., & van Overveld, F. J. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002348 · Cited by 1
Biscaglia, G., Gentile, A., Parente, P., Calvo, A., Fontana, R., Continisio, A., Brina, A. L. P. D., Ciardiello, D., McIlwain, G., Latiano, A., et al. (2025) · Nutrients · doi:10.3390/nu17233788 · Cited by 1
Nieznanska, A., Statkiewicz, M., Sandowska-Markiewicz, Z., Unrug-Bielawska, K., Majewska, A., Kocik-Krol, J., Czepiel, M., Gałuszka-Bulaga, A., Mikuła, M., Ostrowski, J., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118868 · Cited by 1
Targeting PTPN22 at Nonorthosteric Binding Sites─A Fragment Approach
Lello, P. D., Wells, M. M., Davis, B. J., Daniels, Z., Garner, T. P., Gazzard, L. J., Harris, R., Hubbard, R. E., Landry, M. L., Martin, B. T., et al. (2026) · ACS Omega · doi:10.1021/acsomega.5c11028 · Cited by 1
Wang, Y., Xie, Y., Fang, Y., Sui, B., Yuan, X., Chen, Y., & Zhang, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1718170 · Cited by 1
Liu, Z., Xie, Y., He, Y., Chen, K., Zhou, M., Ha, G., Duan, L., Zhao, Z., & Cai, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1723860 · Cited by 1
Ni, Z., Gu, J., Qiu, Q., Li, Y., Tian, Z., Liu, G., Mei, J., Yang, J., & Sun, L. (2026) · BMC Cancer · doi:10.1186/s12885-026-15652-9 · Cited by 1
Shelton, W. J., Mathews, A. P., Siegel, E. R., & Rodriguez, A. (2026) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-750 · Cited by 1
Xiao, S.-Y., Ji, Y.-M., Liu, Y., Lv, Y., Dong, Y., Liu, M.-C., Lu, Y.-H., Cui, P.-F., Li, T., Cui, X., et al. (2026) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-aw-1240 · Cited by 1
Liu, X., Cai, R., Meng, Y., Xu, Y., Wang, B., Liu, M., Wang, Y., Yu, Y., Lu, C., Wei, Y., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105220 · Cited by 1
New and Emerging Drug Reactions
Chu, E. Y., Curry, J. L., & Nguyen, C. (2026) · Dermatologic Clinics · doi:10.1016/j.det.2026.01.009 · Cited by 1
Innovative Strategies of Nanocapsules for Maximizing Efficacy in Tumor Immunotherapy
Jia, Y., Wang, C., Liu, W., Xu, Z., Zhu, W., & Liu, Z. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s578618 · Cited by 1
Evidence that non-cognate proteinogenic amino acids generate immunogenic neoepitopes
Rodgers, K. J. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.111349 · Cited by 1
Almalki, W. H. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119259 · Cited by 1
Diao, Z., Wang, Y., Mu, S., Wu, X., Yu, S., & Wang, Z. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1756245 · Cited by 1
Li, M., Duan, D., Liu, C., & Xiong, Q. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2643042 · Cited by 2
Dobrovolskaia, M. A. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2645394 · Cited by 1
Chen, B., Jia, Y., Meng, L., & Hu, N. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1764908 · Cited by 1
Li, Z., Zhou, C.-K., & Sun, Z. (2026) · Oncogene · doi:10.1038/s41388-026-03758-0 · Cited by 1
Shih, Y., Wang, S.-J., Fan, C.-T., Lu, T.-F., Chen, Y., Sun, L., Hsu, S.-T., Tseng, J.-J., & Lu, C.-H. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04379-y · Cited by 1
Chen, Y., Ye, Z., Wang, Y., Liang, S., & Zhang, D. X. (2026) · Cancer Drug Resistance · doi:10.20517/cdr.2025.213 · Cited by 1
Loss of SHP-1 in CD11c+ cells impairs anti-tumor immunity
Galán, M. Á., Hernández‐García, E., Munné, P., Redondo‐Urzainqui, A., Cueto, F. J., Sicilia, J., Callejas, S., Rey-Martín, M. A., Dopazo, A., Sancho, D., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1710547 · Cited by 1
Wang, Z., Cai, X., Pei, G., Cheng, X., Tian, L., Zhou, Y., Shi, W., Yang, J., Dong, J., & Li, Y. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08189-9 · Cited by 1
Shang, Y., 王双冉, Yan, Y., Tian, E., She, L., & Ma, Z. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050557 · Cited by 1
Awada, A., Charbel, N., Faraj, S., Hassan, M., Awada, D., Issa, A., Nasr, W., Meski, S. E., Hatahet, Z., Tarhini, A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104178 · Cited by 1
Reshaping tumor immunity by targeting SUMOylation: A novel immunotherapeutic strategy
Yi, M., Wu, X., Guo, P., Yu, X., & Li, W. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189611 · Cited by 1
Dooley, G. D., Li, H., Agomuoh, I., Al-Saghir, F., & Arsene, C. (2026) · Cureus · doi:10.7759/cureus.109548 · Cited by 1
Yuan, F., Li, Y., Cui, L., Wang, M., Peng, D., Cheng, X., Mi, P., Zhang, K., Lu, M., Meng, X., et al. (2026) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2026.218126 · Cited by 1
Li, Y., & Hao, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1873528 · Cited by 1
Xia, X., Yu, T., Sun, H., Li, J., Liu, F., & Zhu, X. (2026) · OncoTargets and Therapy · doi:10.2147/ott.s606668 · Cited by 1
Nawa, S., Fujita, M., Ohno, M., Kuramitsu, S., Nohira, S., & Saito, R. (2026) · Cancers · doi:10.3390/cancers18142252 · Cited by 1
Le, F., Huang, X., Jiang, Y., Lv, S., & Chen, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1826288 · Cited by 1
Roslei, A. S. M., Huri, H. Z., Pratama, D. A. O. A., Azemi, A. K., Kari, Z. A., Yasin, I. S. M., Hashim, N. M., Ghazali, M. F., Norpi, A. S. M., Jalil, M. F. A., et al. (2026) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-026-00394-3 · Cited by 1
Exploiting DNA damage tolerance for precision oncology
Bhat, A., Lahane, G. P., PANDITA, R. K., Bacolla, A., Hoden, B., Ramos, K. S., Krishnan, S., Sarkar, P. S., Dhar, A., Tainer, J. A., et al. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.08.003 · Cited by 1
Late-Onset Angioimmunoblastic T-cell Lymphoma During Nivolumab Treatment for Melanoma
Miyashita, A., Murao, T., Shimura, Y., Okamoto, H., Nagata, H., Onishi, A., Fujino, T., Mizutani, S., Tsukamoto, T., & Kuroda, J. (2025) · Cureus · doi:10.7759/cureus.89042 · Cited by 1
Zhu, J., Yu, C. H., Xu, X., Zou, C., Li, J., Wang, R., Li, X., Sun, A., Wang, S., & Jiang, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1619733 · Cited by 1
Zhao, J., Chen, Y., Wu, Q., Wu, M., Wu, S., Ouyang, W., He, Z., Xiao, R., Dai, J. Y., Zhang, W., et al. (2025) · doi:10.22541/au.175100817.71275086/v1 · Cited by 1
Ma, W., Miao, L., Liu, S., Zeng, Z., Li, J., Wang, F., Shen, N., Yang, Z., Gao, L., & Wang, C. (2024) · Research Square · doi:10.21203/rs.3.rs-5612703/v1
Popova, E., Zhelyazkova, Z., Sofiyanski, T., Sergieva, S., & Krasteva, R. (2025) · Preprints.org · doi:10.20944/preprints202504.0510.v1
Research Progress on the Role of Immune Checkpoint Inhibitors in Liver Cancer Therapy
Gong, Z. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.22215
Navigating the latest advancement & frontiers in cancer immunotherapy
Gaikwad, S. S., Wani, S. V., Sonawane, P., Thejaswini, A., Lohakare, O. K., Kshirsagar, P., & Gowtham, M. (2025) · Next research. · doi:10.1016/j.nexres.2025.100401
Targeting the Tumor Microenvironment in Hodgkin Lymphoma: Challenges and Therapeutic Strategies
Laddaga, F. E., Pinto, P., Daraia, B., D’amato, A., D’Oronzo, S., Martinotti, S., & Gaudio, F. (2025) · Biocell · doi:10.32604/biocell.2025.063572
Lin, S., Liu, Y., Zhao, F., Jiang, Q., Yang, S., Zhang, H., Feng, B., & Gan, W. (2025) · PubMed Central · doi:10.12182/20250360104
Triantafillidis, J. K., & Papalois, A. E. (2025) · Gastrointestinal Tract · doi:10.54844/git.2025.887
Grabowska, H., & Chmiel, P. (2025) · Family Medicine & Primary Care Review · doi:10.5114/fmpcr.2025.152621
Mechanisms and Emerging Targeted Therapies of Uterine Serous Carcinoma
Tian, Z. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.au26856
Nimkar, S., Nair, N., & Wankhade, R. (2025) · The Egyptian Journal of Haematology · doi:10.4103/ejh.ejh_38_25
Gaggero, G., Myrtaj, P., Battaglia, T., Palo, F., & Vellone, V. G. (2025) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000003131
Základy všeobecnej klinickej onkológie
Šafčák, D. (2025) · doi:10.33542/zvk-0461-3
Immune Checkpoint Inhibitors: An Innovative Direction in Cancer Immunotherapy
Xie, X. (2025) · Academic Journal of Science and Technology · doi:10.54097/a18j2762
Neue Medikamente, neue Nebenwirkungen? – Nebenwirkungen von Immuntherapien
Häring, M. (2025) · TumorDiagnostik & Therapie · doi:10.1055/a-2649-3098
Schmidt, F., Wu, K. X., Purwanti, Y. I., Tan, N., Carbajo, D., Xin, B. K., Wilm, A., Fehlings, M., MacLeod, D. T., Nardin, A., et al. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf631.001
Tanganho, M. I. B. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
A novel prognostic and immune-related biomarker KCNC3 in colorectal cancer: a pan-cancer analysis
Xia, K., Zhu, H.-C., Lai, F.-Y., Li, Z., Wang, W., & Wang, N. (2025) · Translational Cancer Research · doi:10.21037/tcr-2025-1318
LAG-3 antagonists for cancer treatment: an updated patent review (2020–2025)
Pérez-Santos, M., Landeta, G., Anaya-Ruíz, M., Martínez‐Morales, P., Flores-Robles, D., Jaramillo-Loranca, B. E., Hernández, G. V., Ramos-Enríquez, R., Dublán‐García, O., Guerrero-González, T., et al. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2614492
Global assessment of hepatic safety in novel immunotherapies: a systematic review and meta-analysis
Ye, M., Dong, Y., Li, X., Zhi, Y., Lu, Y., Tang, J., Zhong, W. H., Lei, X., Mao, Y., Huang, S., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1677998
Nakassa, A. C. I., Facchin, M. P. S., Carregaro, V., & Cruz, A. A. V. E. (2026) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000003184
Role of Immunotherapy and Targeted Agents to Treat Brain Metastases
Hajdari, N., & Peereboom, D. M. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000806
Guarding the heart in the era of immunotherapies: insights for cardio-oncology practice
Iram, U., & Lebeche, D. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1762239
CCT7 predicts poor prognosis and correlates with immune infiltration in colonic adenocarcinoma
Li, W., Shi, Q., Mu, Y., Li, C., Zhao, W., & Han, N. (2026) · Journal of Molecular Histology · doi:10.1007/s10735-026-10715-4
Yuan, M., Fang, W., Liu, B., Tong, Y., Cheng, J., Zhong, H., & Lv, W. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm50279
Saxena, M., Ampudia-Mesias, E., Dhawan, S., Frederico, S. C., Cheng, X., Neil, E. C., Bose, R., Kohanbash, G., Moertel, C. L., & Olin, M. R. (2026) · medRxiv · doi:10.64898/2026.02.10.26345679
Shi, H., Wang, J., Wang, Z., Li, Y., Yu, T., Qin, Y., & Lv, J. (2026) · Research · doi:10.34133/research.1210
Role of immunotherapy and immune checkpoint inhibitors in cancer therapy
Singh, S., Sharma, N., Behl, T., Arora, S., Kumar, P., Srivastava, S., & Kishore, L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-31592-3.00015-7
Qian, Y., Yuntao, Z., Weiwu, C., Kong, Y., & Liyuan, Z. (2026) · Diseases & Research · doi:10.54457/dr.202601004
Castillo-Peña, A., Boyero, L., Benedetti, J. C., Sánchez-Gastaldo, A., Alonso, M. D., Muñoz-Fuentes, M. A., Valdivia, M. L., Bernabé-Caro, R., & Molina‐Pinelo, S. (2026) · medRxiv · doi:10.64898/2026.03.12.26348220
Dekker, M., Hempenius, M. A., de Bock, G. H., van Kruchten, M., van Vugt, M. A. T. M., Siebers, A. G., & van der Vegt, B. (2026) · Laboratory Investigation · doi:10.1016/j.labinv.2026.106121
Barden, M., Harrer, D. C., & Abken, H. (2026) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2026063886
Zhang, D. L., Zhang, X., Liu, X., Li, R., & Huang, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1741760
Overview of dendritic cell vaccines for brain tumors
Bergsneider, B. H., & Liau, L. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27356-8.00062-0
Chen, Y., Zhang, C.-L., Li, Y. P., Liu, C.-F., Jiang, H.-Y., Yang, Y., Wang, H., & Pang, M. (2026) · BMC Cancer · doi:10.1186/s12885-026-15946-y · Cited by 1
Hammond, S. T., Brandt, L., Kong, A. L., White, S. B., Lewandowski, D., & Beyer, A. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.319865
de Miranda, F. S., Babcock, R. L., Mahecha, M. F., Gukhool, P. J., Boligala, G. P., Garcia, A. K., Martinez‐Marin, D., Oliver, A. G., Hintelmann, T., Furr, K. L., et al. (2026) · ImmunoTargets and Therapy · doi:10.2147/itt.s581990
Ma, Y., Jiang, J., & Han, Y. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00191
Dupilumab for the Treatment of Refractory Cutaneous Immune-Related Adverse Events: A Case ReportPreprint
Luo, Z., & Gong, J. (2026) · Research Square · doi:10.21203/rs.3.rs-9460962/v1
Orchestrating mast cell for cancer immunotherapy
Li, S., Lv, S.-J., Fu-hua, Y., & Sun, Z. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116761
Chouksey, G., Singhal, K., Arya, N., Parihar, A., & Agrawal, A. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-10731-w
Cao, B., Ai, M., Huang, P., & Zhong, H. (2026) · Oncology Letters · doi:10.3892/ol.2026.15641
Figueroa-Protti, L., & Mora, J. (2026) · Revista del colegio de microbiólogos y químicos clínicos de Costa Rica · doi:10.66675/xosq3099
Computational Design of mRNA-Based Cancer Immunotherapies
Kovačić, D., Huseinbegović, S. I., Muratović, A. K., & Jahibasic, M. (2026) · Springer eBooks · doi:10.1007/978-3-032-20428-8_2
Zhang, J., Zheng, J., Wang, Y., Tian, J. H., & Zhang, W. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.05.017
Strizova, Z. O. (2026) · Vnitřní lékařství · doi:10.36290/vnl.2026.035
Design of Therapeutic Vaccines Based on the Tn Antigen
Bretón, C. (2026) · RIUR (Universidad de La Rioja)
Chiloiro, S., Sanctis, S. A. D., Parente, B., Giampietro, A., D’Angelo, T., Palluzzi, E., Rossi, E., Vertechy, L., Vita, E., Paris, I., et al. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10058-1
Shi, X., Wu, C., & Deng, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1859114
Hu, D., Duan, J., Xie, P., Li, J., Zhao, L., Chen, B., Lu, R., Tang, H., Zheng, X. H., & Qu, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1809975
Pembrolizumab-associated immune-related hepatitis: a retrospective case report analysis
Chen, K.-Q., Chen, Y., Peng, J.-F., Huang, Y., & Liu, X. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1823347
Calvo, C. I. J. (2026) · Academica-e (Universidad Pública de Navarra)
Rigopoulos, C. P., Georgakopoulos‐Soares, I., & Zaravinos, A. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48060641
Tian, R., Cui, X., Wang, L., Yan, L., & Wang, P. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13834-1
Khanna, K., Maki, M. A. M. A., Karwasra, R., Sharma, I., Bahere, M. H., Tayyab, S., Sharma, N., Rajagopal, M. S., Goel, B., & Raza, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43846-2.00021-0
Jainta, P., Wicher, A., Podyma, N., Kempska, I., Harmansa, P., Gwóźdź, J., Szczygłowski, Z., Torbicka, A., Zieleziński, P., & Fryszkiewicz, P. (2026) · Quality in Sport · doi:10.12775/qs.2026.60.72895
Ramalingam, A. R., Köhler, Z. M., Ferdinandy, P., & Varga, Z. V. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70548
van de Wetering, R., Kampstra, A. S. B., Kester, M. G. D., Tjokrodirijo, R. T. N., de Ru, A. H., van Veelen, P. A., Fehres, C. M., Heemskerk, M. H. M., & Toes, R. E. M. (2026) · Journal of Autoimmunity · doi:10.1016/j.jaut.2026.103581
Leveraging multimodal cancer immunotherapy to amplify the efficacy of oncolytic viruses
Cai, Q., Zhang, L., Kong, L., Fang, J., Xu, J., Gu, X., WuJun, L. I., Jiang, C., & Wu, J. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00805-0
Lv, Y., Zheng, D., Zhou, Z., Dai, Z., Wei, S., Liu, X., Lan, X., Gao, Z., & Qin, C. (2026) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2026.102798
Kuan, L., Jia, Z., 鲁海文, Wang, Q., Haihui, H., Yan, Z., Wang, Y., & Liu, X. (2026) · Discover Oncology · doi:10.1007/s12672-026-05544-6
Neoadjuvant therapy for NSCLC: From monotherapy to precision combination therapy
Mao, Q., Mo, H., Zhang, K., Wang, P., & Li, X. D. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105472
Metadata
- Authors
- Arafat Hossain, M.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2024-12
- Volume
- 143
- Issue
- Pt 2
- Pages
- 113365
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W4403679157
- Cited by
- 178
- References
- 626
- FWCI
- 27.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.